Intra-articular hyaluronan therapy

Foot and Ankle Clinics

Volumn 8, Issue 2, 2003, Pages 221-232

  Marshall, K Wayne ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIC ACID;

ANKLE; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; FOOT; FOOT DISEASE; HUMAN; OSTEOARTHRITIS; REVIEW; SUPPLEMENTATION; SYNOVIAL FLUID; VISCOSUPPLEMENTATION; ANIMAL; INTRAARTICULAR DRUG ADMINISTRATION; JOINT; METABOLISM; METHODOLOGY;

ANIMALS; CLINICAL TRIALS; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; JOINTS; OSTEOARTHRITIS; RESEARCH DESIGN;

EID: 2942622482     PISSN: 10837515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-7515(03)00046-9     Document Type: Review

References (83)

1. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
2. Muehleman C, Chubinskaya S, Cole AA, Noskina Y, Arsenis C, Kuettner KE. Morphological and biochemical properties of metatarsophalangeal joint cartilage. J Am Podiatr Med Assoc 1997;87:447-59.
3. Cole AA, Kuettner KE. Molecular basis for differences between human joints. Cell Mol Life Sci 2002;59:19-26.
4. Eger W, Schumacher BL, Mollenhauer J, Kuettner KE, Cole AA. Human knee and ankle cartilage explants: catabolic differences. J Orthop Res 2002;20:526-34.
5. Lumsden JM, Caron JP, Steffe JF, Briggs JL, Arnoczky SP. Apparent viscosity of the synovial fluid from mid-carpal, tibiotarsal, and distal interphalangeal joints of horses. Am J Vet Res 1996;57:879-83.
6. Lane Smith R, Trindade MC, Ikenoue T, et al. Effects of shear stress on articular chondrocyte metabolism. Biorheology 2000;37:95-107.
7. Balazs EA, Watson D, Duff IF, Roseman S. Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritic human fluids. Arthritis Rheum 1967;10:357-76.
8. Balazs EA. The physical properties of synovial fluid and the special role of hyaluronic acid. In: Helfet A, editor. Disorders of the knee. Philadelphia: JB Lippincott; 1974. p. 63-75.
9. Balazs EA, Denlinger JL. Sodium hyaluronate and joint function. Journal of Equine Veterinary Science 1985;5:217-28.
10. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. Journal of Rheumatology 1993;20(Suppl 39):3- 9.
11. Hirota W. Intra-articular injection of hyaluronic acid reduces total amounts of leukotriene C4, 6-keto-prostaglandin F1α, prostaglandin F2α and interleukin-1β in synovial fluid of patients with internal derangement in disorders of the temporomandibular joint. Br J Oral Maxillofac Surg 1998;36:35-8.
12. Srejic U, Calvillo O, Kabakibou K. Viscosupplementation: a new concept in the treatment of sacroiliac joint syndrome: a preliminary report of 4 cases. Reg Anesth Pain Med 1999;24:84-8.
13. Brocq O, Tran G, Breuil V, Grisot C, Flory P, Euller-Ziegler L. Hip osteoarthritis: short-term efficacy and safety of viscosupplementation by hylan G-F 20. An open-label study in 22 patients. Joint Bone Spine 2002;69:388-91.
14. Chevalier X, Conrozier T, Bertin P, Bailleul F, Vignon E. Treatment of patients with symptomatic hip OA - a pilot study with intra-articular hylan G-F 20 (Synvisc®) [abstract]. Presented at the American College of Rheumatology 64th Annual Scientific Meeting. Philadelphia, October 30-November 3, 2000.
15. Yustin D, Kryshtalskyj B, Galea A. Use of hylan G-F 20 for viscosupplementation of the temporomandibular joint for the management of osteoarthritis: a case report. J Orofacial Pain 1995;9:375-9.
16. Nazarian LN, Rawool NM, Martin CE, Schweitzer ME. Synovial fluid in the hindfoot and ankle: detection of amount and distribution with US. Radiology 1995;197:275-88.
17. Balazs EA, Briller SO, Denlinger JL. Na-hyaluronate molecular size variations in equine and human arthritic synovial fluids and the effects on phagocytic cells. In: Talbott JH, editor. Seminars in arthritis and rheumatism. New York: Grune & Stratton; 1981. p. 141-3.
18. Balazs EA. Viscoelastic properties of hyaluronic acid and biological lubrication [proceedings of the symposium Prognosis for Arthritis: Rheumatology Research Today and Prospects for Tomorrow, 1967]. Univ Mich Med Cent J 1968;9(Suppl):255-9.
19. al-Assaf S, Meadows J, Phillips GO, Williams PA. The application of shear and extensional viscosity measurements to assess the potential of hylan in viscosupplementation. Biorheology 1996;33:319-32.
20. Weiss C, Band P. Basic principles underlying the development of viscosupplementation for the treatment of osteoarthritis. J Clin Rheumatol 1999;5(Suppl):S2-11.
21. Balazs EA. The physical properties of synovial fluid and the special role of hyaluronic acid. In: Helfet A, editor. Disorders of the knee. 2nd edition. Philadelphia: JB Lippincott; 1982. p. 61-74.
22. Peyron JG. A new approach to the treatment of osteoarthritis: viscosupplementation. Osteoarthritis Cartilage 1993;1:85-7.
23. Laurent TC. Structure of hyaluronic acid. In: Balazs EA, editor. Chemistry and molecular biology of the intercellular matrix. New York: Academic Press; 1970. p. 703-32.
24. Balazs EA, Leshchiner A, inventors; Biomatrix Inc., assignee. Cross-linked gels of hyaluronic acid and products containing such gels. US patent 4 636 524. January 13, 1987.
25. Balazs EA, Leshchiner E, Larsen NE, Band P. Applications of hyaluronan and its derivatives. In: Gebelein CG, editor. Biotechnological polymers. Lancaster (PA): Technomic Publishing Co. Inc.; 1993. p. 41-65.
26. Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res Clin Exp 1994;55:220-32.
27. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998;20:410-23.
28. Dougados M, Nguyen M, Listrat V, Amor B. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage 1993;1:97-103.
29. Altman RD, Moskowitz R, Hyalgan Study Group. Intraarticular sodium hyaluronate (Hyalgan®) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. J Rheumatol 1998;25:2203-12.
30. Adams ME, Atkinson MH, Lussier AJ, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc®) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 1995;3:213-25.
31. Dickson DJ, Hosie G, English JR. The Primary Care Rheumatology Society OA Knee Study Group. A double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. J Clin Res 2001;4:41-52.
32. Grecomoro G, Martorana C, Di Marco C. Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trial versus placebo. Pharmatherapeutica 1987;5:137-41.
33. Corrado EM, Peluso GF, Gigliotti S, et al. The effects of intra-articular administration of hyaluronic acid in osteoarthritis of the knee: a clinical study with immunological and biochemical evaluations. Eur J Rheumatol Inflamm 1995;15:47-56.
34. Carrabba M, Paresce E, Angelini M, Re KA, Torchiana EEM, Perbellini A. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. Eur J Rheumatol Inflamm 1995;15:25-31.
35. Dixon ASJ, Jacoby RK, Berry H, Hamilton EBD. Clinical trial of intra-articular injection of sodium hyaluronate in patients with osteoarthritis of the knee. Curr Med Res Opin 1988;11:205-13.
36. Henderson EB, Smith EC, Pegley F, Blake DR. Intra-articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: a randomised, single centre double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy. Ann Rheum Dis 1994;53:529-34.
37. Creamer P, Sharif M, George E, et al. Intra-articular hyaluronic acid in osteoarthritis of the knee: an investigation into mechanisms of action. Osteoarthritis Cartilage 1994;2:133-40.
38. Dahlberg L, Lohmander LS, Ryd L. Intraarticular injections of hyaluronan in patients with cartilage abnormalities and knee pain. A one-year double-blind, placebo-controlled study. Arthritis Rheum 1994;37:521-8.
39. Lohmander LS. A controlled, randomized, double-blind multicenter trial of intra-articular hyaluronan treatment in osteoarthrosis of the knee. Acta Orthop Scand 1995;66(Suppl 265):35-6.
40. Lohmander LS, Dalén N, Englund G, et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Ann Rheum Dis 1996;55:424-31.
41. Synvisc [package insert]. Ridgefield, NJ: Genzyme Biosurgery, Inc; 1999.
42. Wobig M, Bach G, Beks P, et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther 1999;21:1549-62.
43. Lussier A, Cividino AA, McFarlane CA, Olyszynski WP, Potasher WJ, de Médicis R. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol 1996;23:1579-85.
44. Raynauld JP, Torrance GW, Band PA, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 1 of 2): clinical results. Osteoarthritis Cartilage 2002;10:506-17.
45. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. Arthritis Rheum 2000;43:1905-15.
46. Goorman SD, Watanabe TK, Miller EH, Perry C. Functional outcome in knee osteoarthritis after treatment with hylan G-F 20. Arch Phys Med Rehabil 2000;81:479-83.
47. Wobig M, Beks P, Dickhut A, Maier R, Vetter G. Open-label multicenter trial of the safety and efficacy of viscosupplementation with hylan G-F 20 (Synvisc) in primary osteoarthritis of the knee. J Clin Rheumatol 1999;5(Suppl):S24-31.
48. Smith MM, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int 1987;7:113-22.
49. Phillips MW. Clinical trial comparison of intra-articular sodium hyaluronate products in the horse. Journal of Equine Veterinary Science 1989;9:39-40.
50. Peluso GF, Perbellini A, Tajana GF. The effect of high and low molecular weight hyaluronic acid on mitogen-induced lymphocyte proliferation. Curr Ther Res Clin Exp 1990;47:437-43.
51. Yasui T, Akatsuka M, Tobetto K, Hayaishi M, Ando T. The effect of hyaluronan on interleukin-1α-induced prostaglandin-E2 production in human osteoarthritic synovial cells. Agents Actions 1992;37:155-6.
52. Akatsuka M, Yamamoto Y, Tobetto K, Yasui T, Ando T. In vitro effects of hyaluronan on prostaglandin E2 induction by interleukin-1 in rabbit articular chondrocytes. Agents Actions 1993;38:122-5.
53. Tobetto K, Nakai K, Akatsuka M, Yasui T, Ando T, Hirano S. Inhibitory effects of hyaluronan on neutrophil-mediated cartilage degradation. Connect Tissue Res 1993;29:181-90.
54. Yoshimi T, Kikuchi T, Obara T, et al. Effects of high-molecular-weight sodium hyaluronate on experimental osteoarthrosis induced by the resection of rabbit anterior cruciate ligament. Clinical Orthopaedics and Related Research 1994;298:296-304.
55. Kikuchi T, Yamada H, Shimmei M. Effect of high molecular weight hyaluronan on cartilage degeneration in a rabbit model of osteoarthritis. Osteoarthritis Cartilage 1996;4:99-110.
56. Darzynkiewicz Z, Balazs EA. Effect of connective tissue intercellular matrix on lymphocyte stimulation. I. Suppression of lymphocyte stimulation by hyaluronic acid. Exp Cell Res 1971;66:113-23.
57. Balazs EA, Darzynkiewicz Z. The effect of hyaluronic acid on fibroblasts, mononuclear phagocytes and lymphocytes. In: Kulonen E, Pikkarainen J, editors. Biology of the fibroblast (papers of the symposium held in Turku, Finland, 1972). London: Academic Press; 1973. p. 237-52.
58. Forrester JV, Balazs EA. Inhibition of phagocytosis by high molecular weight hyaluronate. Immunology 1980;40:435-46.
59. Tobetto K, Yasui T, Ando T, et al. Inhibitory effects of hyaluronan on [14C]arachidonic acid release from labeled human synovial fibroblasts. Jpn J Pharmacol 1992;60:79-84.
60. Aihara S, Murakami N, Ishii R, et al. Effects of sodium hyaluronate on the nociceptive response of rats with experimentally induced arthritis. Folia Pharmacologica Japonica 1992;100:359-65.
61. Gotoh S, Onaya J-I, Abe M, et al. Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. Ann Rheum Dis 1993;52:817-22.
62. Belmonte C, Pozo MA, Balazs EA. Modulation by hyaluronan and its derivatives (hylans) of sensory nerve activity signalling articular pain. In: Laurent TC, editor. The chemistry, biology, and medical applications of hyaluronan and its derivatives. Proceedings of the Wenner-Gren Foundation International Symposium. Volume 72. Stockholm, Sweden, September 18- 21, 1996. London: Portland Press; 1997. p. 205-17.
63. Pozo MA, Balazs EA, Belmonte C. Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. Exp Brain Res 1997;116:3-9.
64. Kawasaki K, Ochi M, Uchio Y, Adachi N, Matsusaki M. Hyaluronic acid enhances proliferation and chondroitin sulfate synthesis in cultured chondrocytes embedded in collagen gels. J Cell Physiol 1999;179:142-8.
65. Han F, Ishiguro N, Ito T, Sakai T, Iwata H. Effects of sodium hyaluronate on experimental osteoarthritis in rabbit knee joints. Nagoya J Med Sci 1999;62:115-26.
66. Frean SP, Abraham LA, Lees P. In vitro stimulation of equine articular cartilage proteoglycan synthesis by hyaluronan and carprofen. Res Vet Sci 1999;67:183-90.
67. Kang Y, Eger W, Koepp H, Williams JM, Kuettner KE, Homandberg GA. Hyaluronan supresses fibronectin fragment-mediated damage to human cartilage explant cultures by enhancing proteoglycan synthesis. J Orthop Res 1999;17:858-69.
68. Sonoda M, Harwood FL, Amiel ME, et al. The effects of hylauronan in tissue healing after meniscus injury and repair in a rabbit model. Am J Sports Med 2000;28:90-7.
69. Homandberg GA, Hui F,Wen C, Kuettner KE,Williams JM. Hyaluronic acid supresses fibronectin fragment mediated cartilage chondrolysis: I. In vitro. Osteoarthritis Cartilage 1997;5:309-19.
70. Williams JM, Plaza V, Hui F, Wen C, Kuettner KE, Homandberg GA. Hyaluronic acid supresses fibronectin fragment mediated cartilage chondrolysis: II. In vivo. Osteoarthritis Cartilage 1997;5:234-40.
71. Goto H, Onodera T, Hirano H, Shimamura T. Hyaluronic acid suppresses the reduction of α2(VI) collagen gene expression caused by interleukin-1β in cultured rabbit articular chondrocytes. Tohoku J Exp Med 1999;187:1-13.
72. Marshall KW, Manolopoulos V, Mancer K, Staples J, Damyanovich A. Amelioration of disease severity by intraarticular hylan therapy in bilateral canine osteoarthritis. J Orthop Res 2000;18:416-25.
73. Smith GNJ, Myers SL, Brandt KD, Mickler EA. Effect of intraarticular hyaluronan injection in experimental canine osteoarthritis. Arthritis Rheum 1998;41:976-85.
74. Abatangelo G, Botti P, Del Bue M, et al. Intraarticular sodium hyaluronate injections in the Pond-Nuki experimental model of osteoarthritis in dogs. I. Biochemical results. Clin Orthop 1989;241:278-85.
75. Larsen NE, Lombard KM, Parent EG, Balazs EA. Effect of hylan on cartilage and chondrocyte cultures. J Orthop Res 1992;10:23-32.
76. Armstrong S, Read R, Ghosh P. The effects of intraarticular hyaluronan on cartilage and subchondral bone changes in an ovine model of early osteoarthritis. J Rheumatol 1994;21:680-8.
77. Adams ME, Lussier AJ, Peyron JG. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of osteoarthritis of the knee. Drug Saf 2000;23:115-30.
78. Jones A, Regan M, Ledingham J, Pattrick M, Manhire A, Doherty M. Importance of placement of intraarticular steroid injections. BMJ 1993;307:1329-30.
79. Jackson DW, Evans NA, Thomas BM. Accuracy of needle placement into the intra-articular space of the knee. J Bone Joint Surg Am 2002;84-A:1522-7.
80. Bliddal H. Placement of intra-articular injections verified by mini air-arthrography. Ann Rheum Dis 1999;58:641-3.
81. Qvistgaard E, Kristoffersen H, Terslev L, Danneskiold-Samsøe B, Torp-Pedersen S, Bliddal H. Guidance by ultrasound of intra-articular injections in the knee and hip joints. Osteoarthritis Cartilage 2001;9:512-7.
82. Waddell D, Estey D, Bricker DC. Viscosupplementation under fluoroscopic control. Am J Med Sports 2001;3:237-41, 249.
83. Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59:936-44.